Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of hydrocortisone dosing in children with congenital adrenal hyperplasia
NL-OMON48168Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of hydrocortisone in congenital adrenal hyperplasia (CAH) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Salivary 17-hydroxyprogesterone concentration and Salivary androstenedione concentration. Started Jun 2019; status: active, not recruiting.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NL-OMON48168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48168.